Business Description
Fennec Pharmaceuticals Inc
NAICS : 325410
SIC : 3741
ISIN : CA31447P1009
Total Employee Number:
35Description
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.06 | |||||
Equity-to-Asset | 0.53 | |||||
Debt-to-Equity | 0.52 | |||||
Debt-to-EBITDA | -2.92 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.34 | |||||
Beneish M-Score | -1.98 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 201 | |||||
3-Year EBITDA Growth Rate | 32.5 | |||||
3-Year EPS without NRI Growth Rate | 31.3 | |||||
3-Year FCF Growth Rate | 13.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 44.63 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.53 | |||||
9-Day RSI | 58.03 | |||||
14-Day RSI | 60 | |||||
3-1 Month Momentum % | 49.74 | |||||
6-1 Month Momentum % | 11.97 | |||||
12-1 Month Momentum % | -3.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.98 | |||||
Quick Ratio | 6.78 | |||||
Cash Ratio | 4.19 | |||||
Days Inventory | 176.25 | |||||
Days Sales Outstanding | 135.91 | |||||
Days Payable | 520.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9 | |||||
Shareholder Yield % | 1.78 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 92.23 | |||||
Operating Margin % | -11.02 | |||||
Net Margin % | -16.42 | |||||
EBITDA Margin % | -13.08 | |||||
FCF Margin % | -11.33 | |||||
OCF Margin % | -11.33 | |||||
ROE % | -76.01 | |||||
ROA % | -14.69 | |||||
ROIC % | -28.73 | |||||
3-Year ROIIC % | 68.91 | |||||
ROC (Joel Greenblatt) % | -43.81 | |||||
ROCE % | -14.24 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 42.13 | |||||
PS Ratio | 6.34 | |||||
PB Ratio | 9.69 | |||||
Price-to-Tangible-Book | 9.69 | |||||
EV-to-EBIT | -48.5 | |||||
EV-to-EBITDA | -49.25 | |||||
EV-to-Revenue | 6.44 | |||||
EV-to-Forward-Revenue | 4.41 | |||||
EV-to-FCF | -56.95 | |||||
Price-to-GF-Value | 1 | |||||
| Price-to-Net-Current-Asset-Value | 11.16 | |||||
| Price-to-Net-Cash | 60.42 | |||||
Earnings Yield (Greenblatt) % | -2.06 | |||||
FCF Yield % | -1.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FENC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fennec Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 50.999 | ||
| EPS (TTM) ($) | -0.29 | ||
| Beta | 2.3138 | ||
| 3-Year Sharpe Ratio | 0.31 | ||
| 3-Year Sortino Ratio | 0.57 | ||
| Volatility % | 65.48 | ||
| 14-Day RSI | 60 | ||
| 14-Day ATR ($) | 0.519205 | ||
| 20-Day SMA ($) | 10.045 | ||
| 12-1 Month Momentum % | -3.76 | ||
| 52-Week Range ($) | 5.65 - 11.31 | ||
| Shares Outstanding (Mil) | 34.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fennec Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fennec Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 125 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 08:30 | In 35 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 34 days | ||
| General meeting for 2026 | 2026-06-10 10:00 | 8.77 (-3.31%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ | 2026-05-19 11:30 | 9.60 (-1.03%) | ||
| First quarter earnings conference call for 2026 | 2026-05-14 08:30 | 6.77 (-3.15%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 6.77 (-3.15%) | ||
| Annual report for 2025 | 2026-03-27 | 6.51 (+6.72%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-24 08:30 | 7.45 (-1.19%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-24 | 7.45 (-1.19%) |
Show
Entries
Fennec Pharmaceuticals Inc Frequently Asked Questions
What is Fennec Pharmaceuticals Inc(FENC)'s stock price today?
The current price of FENC is $10.49. The 52 week high of FENC is $11.31 and 52 week low is $5.65.
When is next earnings date of Fennec Pharmaceuticals Inc(FENC)?
The next earnings date of Fennec Pharmaceuticals Inc(FENC) is 2026-08-14 Est..
Does Fennec Pharmaceuticals Inc(FENC) pay dividends? If so, how much?
Fennec Pharmaceuticals Inc(FENC) does not pay dividend.
Guru Commentaries on NAS:FENC
No articles.
Press Release
Articles on Fennec Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers